Compared to BTZ single treatment, 3-MA obviously sensitized MCL cells to BTZ, and more significant efficacy of BTZ and 3-MA was observed in resistant REC-1 and BACH2KD Jeko cells (Fig. 5a, b). The gene discussed is CASC3; the disease is mantle cell lymphoma.